drugset / Trial / NCT00044447

Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

NCT00044447

Phase 3 Completed 170 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.

Timeline

Start
2001-05
Primary completion
Completion
2002-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule